Every material Form 8-K Steris has filed with the SEC since May 08, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 4, 2026, STERIS and its subsidiaries entered a new $1.6 billion revolving credit facility that replaces the existing credit agreement dated October 7, 2024, and a separate delayed draw term loan of up to $500 million. The term loan can be drawn only if STERIS completes its acquisition of Xodus Medical, Inc. For shareholders, the filing adds committed borrowing capacity tied to that acquisition, and the filing does not state the acquisition price or the amount that will be borrowed.
Revolving credit facility of $1,600 million matures on November 4, 2031, with an incremental increase of up to $800 million available.
Delayed draw term loan of up to $500 million can be used only after the Xodus Medical Acquisition is consummated and terminates if that deal is validly terminated or the outside date occurs.
Term loan matures five years after the acquisition closing date; no principal is due in year one, then 1.25% quarterly in years two and three and 1.875% quarterly in years four and five.
No borrowings were incurred to refinance the existing credit agreement at closing, and all term loan lenders are also lenders under the revolver.
STERIS plc reported total revenue of $1.6 billion for the second quarter of fiscal 2027, representing a 9% increase compared to the prior year period. Net income rose to $213.7 million, and the company updated its full-year adjusted EPS outlook to a range of $11.35 to $11.55.
Total revenue for Q2 fiscal 2027 reached $1.6 billion, up 9% year-over-year.
Diluted EPS as reported was $2.19, while adjusted diluted EPS increased to $2.94.
Full-year fiscal 2027 adjusted EPS outlook was raised to a range of $11.35 to $11.55.
The company approved a targeted restructuring plan anticipating total charges of approximately $45 million.
STERIS, through subsidiary STERIS Corporation, agreed on October 11, 2026 to acquire Xodus Medical, a Pennsylvania specialty surgical products business, for $2.1 billion in cash at closing, with up to $150 million more tied to calendar 2028 performance targets. The deal is expected to be financed mainly with debt, backed by a $2.0 billion bridge financing commitment, and is expected to close by December 31, 2026, subject to regulatory approvals.
Cash price: $2.1 billion at closing, subject to customary adjustments, plus up to $150 million in earnout tied to calendar 2028 targets
Financing: expected to be funded primarily with debt; $2.0 billion senior unsecured bridge facility from JPMorgan Chase Bank and Goldman Sachs Bank USA
Timing: expected to close by December 31, 2026; either party may terminate if not closed by July 12, 2027, extendable to January 11, 2028
STERIS reported fiscal 2027 first-quarter revenue up 7% to $1.5 billion and diluted EPS of $2.04, up from $1.79, with adjusted EPS of $2.59 versus $2.34. It reiterated its full-year revenue and adjusted EPS guidance, but raised its capital expenditure outlook and lowered its free cash flow outlook, and it announced a consolidation of U.S. chemistries manufacturing that includes closing facilities in St. Louis, Missouri, and Plymouth, Minnesota.
Q1 fiscal 2027 revenue rose 7% to $1.5 billion; Healthcare revenue grew 8% to $1.05 billion.
Free cash flow fell to $279.6 million from $326.5 million; operating cash flow was $367.1 million versus $420.0 million.
Expected pre-tax restructuring charges of $55 million to $70 million, with completion anticipated during fiscal 2030.
Full-year free cash flow outlook cut to about $800 million from $850 million, while capital expenditures are now expected at about $450 million versus $375 million.
STERIS reported fiscal 2026 revenue from continuing operations up 9% to $5.9 billion, with reported diluted EPS from continuing operations rising to $7.93 from $6.16. The board approved a new $1 billion share repurchase program and guided fiscal 2027 adjusted EPS to $11.10 to $11.30, which would be an increase of 9% to 11% over fiscal 2026 adjusted EPS of $10.17.
Full-year revenue from continuing operations was $5.9 billion, up from $5.5 billion, with constant currency organic growth of 7%.
Reported diluted EPS from continuing operations was $7.93 versus $6.16; adjusted EPS was $10.17 versus $9.22.
Fiscal 2027 outlook calls for revenue growth of 7-8% and free cash flow of about $850 million.
The new $1 billion buyback replaces the prior authorization and may be suspended or discontinued at any time.
STERIS plc appointed Pierre Boulud, CEO of bioMérieux, to its Board of Directors effective May 5, 2026, and increased the Board from nine to ten members. Director Richard C. Breeden, who has served 18 years, will not stand for reelection at the 2026 Annual General Meeting, and the company said his decision was not due to any disagreement with the company. The filing reports no financial results or guidance changes, so the event mainly affects board composition.
Pierre Boulud was appointed director effective May 5, 2026; the Board increased from nine to ten members.
Richard C. Breeden notified the company on May 1, 2026 that he will not stand for reelection at the 2026 Annual General Meeting, after 18 years as a director.
Boulud has been CEO of bioMérieux since June 2023 and will receive a prorated fee of $76,989 for the rest of the 2025-26 term, paid in career restricted stock units.
STERIS plc amended the transition agreement with former Chief Financial Officer Michael J. Tokich, dated August 5, 2025, on March 31, 2026. Mr. Tokich will serve as a part-time senior financial advisor from April 1, 2026 through March 31, 2027, at a reduced base salary of $60,000 and without his health, dental and other employee benefits. The change affects one former executive's compensation and does not alter the company's reported results or guidance.
Amendment dated March 31, 2026 modifies the August 5, 2025 Transition Agreement with former CFO Michael J. Tokich
Part-time senior financial advisor role runs April 1, 2026 through March 31, 2027
Annual base salary reduced to $60,000 during the extended period; health, dental, life insurance and other benefit plans no longer apply
Cash bonus is possible at the CEO's discretion, subject to approval by the Compensation and Organization Development Committee
STERIS reported fiscal 2026 third-quarter results for the quarter ended December 31, 2025, with revenue up 9% to $1.5 billion and diluted EPS from continuing operations of $1.96, compared with $1.75 a year earlier. The company kept its fiscal 2026 adjusted EPS outlook of $10.15 to $10.30, but raised its estimate of the tariff hit to pre-tax profit to approximately $55 million from approximately $45 million.
Q3 revenue from continuing operations was $1,496.2 million, up from $1,370.6 million; constant currency organic growth was 8%.
Q3 diluted EPS from continuing operations was $1.96 versus $1.75; adjusted EPS was $2.53 versus $2.32.
Fiscal 2026 outlook was maintained: adjusted EPS of $10.15 to $10.30 and revenue growth of 8% to 9%.
Estimated tariff impact on pre-tax profit rose to approximately $55 million from approximately $45 million.
STERIS reported fiscal 2026 second-quarter results for the quarter ended September 30, 2025, with revenue from continuing operations up 10% to $1.5 billion and diluted EPS from continuing operations rising to $1.94 from $1.51 a year earlier. The company raised its fiscal 2026 adjusted EPS outlook to $10.15 to $10.30 and its free cash flow expectation to about $850 million, which points to higher expected per-share earnings and cash generation for shareholders.
Q2 revenue from continuing operations rose to $1,460.3 million from $1,328.9 million; constant currency organic growth was 9%.
Diluted EPS from continuing operations was $1.94 vs. $1.51; adjusted EPS was $2.47 vs. $2.14.
Fiscal 2026 adjusted EPS outlook raised to $10.15 to $10.30 from $9.90 to $10.15; free cash flow expected at about $850 million vs. $820 million prior.
Tariffs are estimated to reduce pre-tax profit by about $45 million, unchanged from prior outlook.
STERIS reported first-quarter fiscal 2026 revenue of $1.4 billion, up 9%, and diluted EPS from continuing operations of $1.79, up from $1.41 a year earlier. The company raised its fiscal 2026 reported revenue growth outlook to 8-9% from 6-7%, while its adjusted EPS outlook of $9.90 to $10.15 was unchanged, and CFO Michael J. Tokich is stepping down with Karen Burton taking over on August 18, 2025.
Q1 fiscal 2026 revenue was $1.4 billion, up 9% from $1.3 billion; diluted EPS from continuing operations was $1.79 versus $1.41, and adjusted EPS was $2.34 versus $2.03.
Fiscal 2026 reported revenue growth outlook raised to 8-9% from 6-7%, mainly due to about 200 basis points of expected favorable currency impact.
Adjusted EPS outlook unchanged at $9.90 to $10.15; estimated tariff impact on pre-tax profit increased to about $45 million from $30 million.
CFO Michael J. Tokich steps down; Karen Burton, currently Vice President and Chief Accounting Officer, becomes Senior Vice President and CFO effective August 18, 2025.
STERIS plc said director Dr. Richard Steeves will retire from its Board of Directors at the Annual Meeting of Shareholders on July 31, 2025, and will not stand for re-election. The company said his decision was not the result of any disagreement with the company on strategy, operations, policies or practices.
Dr. Richard Steeves notified the company on July 1, 2025 of his retirement from the Board
Retirement takes effect on the date of the Annual Meeting, scheduled for July 31, 2025
Steeves served 10 years as a Director, according to the company
STERIS reported fiscal 2025 full-year revenue from continuing operations up 6% to $5.5 billion and diluted EPS from continuing operations of $6.16, up from $5.55. Fourth-quarter as reported diluted EPS slipped to $1.48 from $1.54 after a $48.2 million Illinois EO litigation settlement charge. The company also gave fiscal 2026 guidance of 6-7% revenue growth and adjusted EPS of $9.90 to $10.15.
Q4 fiscal 2025 revenue rose 4% to $1.5 billion; as reported diluted EPS was $1.48 versus $1.54 a year earlier
Full-year adjusted diluted EPS was $9.22, up from $8.20 in fiscal 2024
Fiscal 2026 outlook: revenue up 6-7% and adjusted EPS of $9.90 to $10.15, with tariffs estimated to reduce pre-tax profit by about $30 million
Free cash flow for fiscal 2025 was $787.2 million, up from $620.3 million
STERIS reported fiscal 2025 third-quarter results for the quarter ended December 31, 2024, with revenue up 6% to $1.4 billion and diluted EPS from continuing operations of $1.75, up from $1.49 a year earlier. The company lowered its fiscal 2025 revenue growth expectation to about 6% from 6.5% to 7.5% and narrowed its adjusted EPS range to $9.05 to $9.15 from $9.05 to $9.25, mainly due to currency. Shareholders get stronger quarterly growth alongside a less optimistic full-year outlook.
Q3 revenue rose 6% to $1.4 billion; diluted EPS from continuing operations was $1.75 versus $1.49
Adjusted diluted EPS was $2.32 versus $2.09 in the prior-year quarter
Fiscal 2025 revenue growth now expected at about 6%, versus prior expectations of 6.5% to 7.5%
Fiscal 2025 adjusted EPS now $9.05 to $9.15, versus $9.05 to $9.25; company cites about a ten cent negative currency impact
STERIS reported fiscal 2025 second-quarter results for the period ended September 30, 2024, with revenue from continuing operations up 7% to $1.3 billion and diluted EPS from continuing operations of $1.51, up from $1.20. The company reiterated its fiscal 2025 outlook, including adjusted EPS of $9.05 to $9.25, so shareholders see higher quarterly profit with no change to guidance.
Revenue rose 7% to $1.3 billion from $1.2 billion a year earlier.
Net income was $150.2 million, or $1.51 per diluted share, versus $119.8 million, or $1.20 per diluted share.
Adjusted EPS was $2.14, up from $1.86 in the prior-year quarter.
Fiscal 2025 adjusted EPS outlook of $9.05 to $9.25 was reiterated, and free cash flow for the first half was $344.5 million.
On October 7, 2024, STERIS and affiliated borrowers entered a $1.1 billion revolving credit agreement with JPMorgan Chase Bank as administrative agent, replacing the credit agreement dated March 19, 2021. The facility matures five years after October 7, 2024, and proceeds will fund general corporate purposes and working capital.
Revolving facility of $1,100 million, expandable by up to $625 million at lenders' discretion
Matures five years after October 7, 2024; interest is based on a base rate or relevant rate plus an applicable margin tied to STERIS's debt rating
Contains customary covenants, including limits on leverage and a minimum interest coverage requirement
Replaces the existing credit agreement dated March 19, 2021
STERIS reported fiscal 2025 first-quarter results for the period ended June 30, 2024. Revenue from continuing operations rose 8% to $1.3 billion, and reported diluted EPS from continuing operations increased to $1.41 from $1.31, while adjusted EPS rose to $2.03 from $1.84. The company reiterated its fiscal 2025 outlook, including adjusted EPS guidance of $9.05 to $9.25, but free cash flow fell to $195.7 million from $214.5 million.
Revenue from continuing operations increased 8% to $1.3 billion from $1.2 billion a year earlier; constant currency organic revenue grew 6%.
Reported diluted EPS from continuing operations was $1.41 versus $1.31; adjusted diluted EPS was $2.03 versus $1.84.
Fiscal 2025 adjusted EPS from continuing operations is expected at $9.05 to $9.25, compared with $8.20 in fiscal 2024.
Free cash flow was $195.7 million versus $214.5 million, which management attributed primarily to the timing of capital spending.
STERIS reported fiscal 2024 fourth-quarter revenue up 10% to $1.5 billion and full-year revenue up 12% to $5.5 billion, and announced a targeted restructuring plan with approximately $100 million in pre-tax charges. The fourth-quarter U.S. GAAP result was a net loss of $1.4 million, or $0.01 per diluted share, compared with net income of $187.2 million a year earlier, as results were negatively impacted by a $206.4 million pre-tax loss tied to the Dental segment and $44.4 million of restructuring charges. The company expects fiscal 2025 adjusted earnings per diluted share of $9.05 to $9.25, compared with $8.20 in fiscal 2024.
Q4 fiscal 2024 revenue rose 10% to $1.5 billion; Q4 U.S. GAAP net loss was $1.4 million, or $0.01 per diluted share, versus net income of $187.2 million a year earlier.
Full-year fiscal 2024 U.S. GAAP EPS was $3.81, up from $1.07; adjusted EPS was $8.83, up from $8.20.
Restructuring plan carries about $100 million in pre-tax charges, with $44.4 million recorded in Q4 and the balance in fiscal 2025; about $50 million is non-cash.
Fiscal 2025 outlook calls for revenue from continuing operations to rise 6.5% to 7.5% and adjusted EPS of $9.05 to $9.25.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Steris filing is on SEC EDGAR ↗. 8-K briefs of other companies →